Bayer AG agreed to acquire Perfuse Therapeutics Inc. for up to $2.45 billion, a strategic deal aimed at expanding its ophthalmology pipeline. The transaction strengthens Bayer’s healthcare franchise and signals continued investment in biotech innovation. The announcement is moderately positive for Bayer and could be sector-relevant within ophthalmology and biotech M&A.
Bayer AG agreed to acquire Perfuse Therapeutics Inc. for up to $2.45 billion, a strategic deal aimed at expanding its ophthalmology pipeline. The transaction strengthens Bayer’s healthcare franchise and signals continued investment in biotech innovation. The announcement is moderately positive for Bayer and could be sector-relevant within ophthalmology and biotech M&A.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.58
